KUALA LUMPUR, 22 September 2025 — Swiss pharma giant Roche Holding AG is set to move its experimental obesity treatment, CT-388, into late-stage clinical trials next year, a decision reflecting its bid to challenge established players in the fast-growing weight-loss drug arena.
CT-388, a dual GLP-1/GIP agonist developed in Roche’s metabolism and obesity portfolio, had already shown promise in early-stage studies. One trial saw patients lose an average of nearly 18.8% of body weight over 24 weeks, though data also raised concerns about side effects such as nausea and vomiting. Roche has downplayed those concerns, saying the incidence rates are comparable to rival treatments.
What’s Driving Roche’s Decision
Roche’s push to late-stage trials comes against a backdrop of sharply rising demand for obesity treatments. Global obesity rates continue to climb and weight-management therapies—especially injectable and combination GLP-1/GIP treatments—have become high priorities for patients, payers, and healthcare providers. Established treatments from Novo Nordisk and Eli Lilly have set a benchmark, but Roche appears confident in CT-388’s differentiators. Roche’s leadership has signalled that despite side-effect reports, the efficacy profile is strong enough to compete.
CT-388’s development path was accelerated following Roche’s acquisition of Carmot Therapeutics, which brought in several promising weight-loss drug candidates. CT-388 is one of the lead molecules from that deal. Roche has also indicated that its obesity pipeline includes CT-996 (an oral GLP-1 candidate), among others, aiming for a portfolio approach combining injectable and oral options.
Challenges & Risk Factors
While the move is bold, it carries risks. Early-stage side effects have caused investor concerns, especially given the high expectations set by CT-388’s early weight-loss efficacy. Roche will need to show that CT-388’s safety profile is acceptable in broader, more diverse patient populations over longer durations. Regulatory review, trial design, dosage optimization, and tolerability will be carefully scrutinised.
Market competition is intense. Novo Nordisk and Eli Lilly already dominate the GLP-1 space, and emerging players and combination therapies are aggressively pursuing same or adjacent mechanisms. Roche’s entry with CT-388 must offer sufficient advantages in efficacy, safety, dosing frequency, or formulation (for example ease of use) to carve out market share. Moreover, pricing and reimbursement will be crucial, particularly in jurisdictions sensitive to drug cost inflation.
Investor Implications
For investors, CT-388’s progression into late-stage trials could be transformational if Roche delivers on its promise. A successful Phase III outcome might put it in the same tier as market leaders, potentially unlocking strong revenue streams starting in the late 2020s. Roche’s broader obesity / weight-management strategy—including oral drug candidates—may enhance its long-term competitiveness, diversification, and margin profile.
However, timelines are long in pharma. Between trial execution, regulatory review, and market launch, there may be years where costs are high and returns unclear. Any misstep—unexpected side effects, regulatory hurdles, or shortcomings in tolerability—could lead to delays or even failure. Investors should watch for data from upcoming trials, how Roche addresses safety concerns, pricing strategy, and how payers respond.
Outlook
Roche’s decision to escalate CT-388 into late-stage trials signals its belief that the obesity treatment market remains ripe for innovation, particularly for therapies that combine strong efficacy with acceptable tolerability. Over the next 12-24 months, Roche will need to deliver compelling trial design, robust safety data, and evidence of durability. If all goes well, CT-388 could become a major contender in obesity therapeutics, challenging incumbents and broadening treatment options for patients.
